USP7 and inflammatory bowel disease: Our recent study indicated that AMBRA1 significantly inhibited the therapeutic effect of infliximab, the widely used monoclonal antibody against TNF‐α, and was highly expressed in patients with no clinical remission after anti‐TNF‐α therapy.[23] Thus, targeting USP7/AMBRA1 complex could be a potential and effective strategy to inhibit intestinal oxidative stress and inflammation for IBD treatment.